Protalix BioTherapeutics, Inc.

We sent you this proxy statement and the enclosed proxy card because the Board of Directors of Protalix BioTherapeutics, Inc. is soliciting your proxy to vote at the 2025 Annual Meeting of Stockholders and any adjournments of the meeting to be held on June 26, 2025 at the offices of our counsel, Gornitzky & Co., at the Vitania Tel Aviv Tower, 20 HaHarash Street, Tel Aviv 6761310, Israel. This proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the meeting and the information you need to know to vote at the meeting.

We anticipate that on or about May 8, 2025, we will begin sending this proxy statement, the attached Notice of Annual Meeting and the form of proxy enclosed to all stockholders entitled to vote at the meeting. Although not part of this proxy statement, we are also sending along with this proxy statement our Annual Report on Form 10-K which includes financial statements for the fiscal year ended December 31, 2024 (the “FY2024 Annual Report”). You can also find a copy of our FY2024 Annual Report on the Internet through the electronic data system called EDGAR provided by the Securities and Exchange Commission, or the SEC, at http://www.sec.gov or through the Investor Relations section of our website at http://www.protalix.com. Our FY2024 Annual Report and the information on our website other than this proxy statement are not part of our proxy soliciting materials. Additional copies of the FY2024 Annual Report are available upon request.